| (Values in U.S. Thousands) | Jun, 2026 | Mar, 2026 | Jun, 2025 | Mar, 2025 | Mar, 2025 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -23,500 | -27,230 | -15,650 | -12,400 | 0 |
| Net Income Growth | +13.70% | -73.99% | -26.21% | unch | unch |
Veradermics Incorporated (MANE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Veradermics Incorporated is a late clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment in prevalent aesthetic and dermatological conditions. Veradermics Incorporated is based in NEW HAVEN, Conn.
Fiscal Year End Date: 12/31